Zoniporide, also called as CP-597,396, is a potent and selective Na(+)/H(+) exchanger (NHE) with high aqueous solubility and acceptable pharmacokinetics for intravenous administration. Zoniporide displays selectivity over other NHE isoforms (Ki values are 14, 2200 and 220000 nM for human NHE1, human NHE2 and rat NHE3 respectively).

Zoniporide dihydrochloride is a potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor with selectivity over other NHE isoforms (Ki = 14, 2200 and 220000 nM for human NHE1, human NHE2 and rat NHE3, respectively). Zoniporide inhibits NHE1-dependent 22Na+ uptake in vitro (IC50 = 14 nM) and protects against cardiac ischemia-reperfusion injury. Zoniporide also exhibits inhibitory effects […]

Zoniporide hydrochloride is a potent and selective inhibitor of Na+/H+ exchanger isoform 1 (NHE-1), which is mostly expressed in the heart. Zoniporide inhibits NHE1-dependent Na+ uptake (IC50: 14 nM) and protects from cardiac ischemia-reperfusion injury (EC50 = 0.25 nM).

Zonisamide is the first agent of this chemical class to be developed as an antiepileptic drug blocks repetitive firing of voltagesensitive sodium channels and reduces voltage-sensitive T-type calcium currents.

Zonisamide is the first agent of this chemical class to be developed as an antiepileptic drug blocks repetitive firing of voltagesensitive sodium channels and reduces voltage-sensitive T-type calcium currents.

Zonisamide-[13C2,15N] is the labelled analogue of Zonisamide, which is a Sulfonamide-derived antiseizure agent and coule be used as a neuroprotective as well as neuroresearch agent.

An isotope labelled Zonisamide. Zonisamide can be used to treat the symptoms of epilepsy and Parkinson’s disease.

An isotope labelled Zonisamide. Zonisamide can be used to treat the symptoms of epilepsy and Parkinson’s disease.

One of the isotopic labelled form of Zopiclone, which is a GABAA receptor agonist and could be used as a sedative as well as hypnotic agent.

One of the impurities of Zopiclone, which is a GABAA receptor agonist and could be used as a sedative as well as hypnotic agent.

One of the impurities of Zopiclone, which is a GABAA receptor agonist and could be used as a sedative as well as hypnotic agent.

Zopiclone N-Oxide-[d8] is a labelled metabolite of Zopiclone.

One of the isotopic labelled form of Zopiclone, which is a GABAA receptor agonist and could be used as a sedative as well as hypnotic agent.

Zopolrestat is an inhibitor of Aldose Reductase(AR). It has been shown to play roles in inflammation and cancer. It is used for the treatment of diabetic nephropathy and cardiac disease. It was developed by Pfizer and was terminated in clinic phase 2 trials.

Zorubicin is a benzoyl-hydrazone derivative of the anthracycline antineoplastic antibiotic daunorubicin. Zorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.

Zosuquidar, also called as LY335979, a cyclopropyldibenzosuberane, was developed as an inhibitor of P-glycoprotein (P-gp). It is undergoing testing in a phase I/II trial clinical study in acute myeloid leukaemia.

Zosuquidar (LY335979) is a potent modulator of P-glycoprotein-mediated multi-drug resistance with a Ki value of 60 nM.

Zotarolimus (INN, codenamed ABT-578) is an immunosuppressant. It is a semi-synthetic derivative of rapamycin. It was designed for use in stents with phosphorylcholine as a carrier. Coronary stents reduce early complications and improve late clinical outcomes in patients needing interventional cardiology.

Zotepine is a 5-HT2A receptor and dopamine D2 receptor antagonist (Ki = 0.69 and 2.3 nM, respectively) used as an atypical antipsychotic for the treatment of schizophrenia. Zotepine also exhibits an antagonistic effect at histamine H1 receptor (IC50 = 8.0 nM).

Labelled Zoxamide. Zoxamide has a low mammalian toxicity but is a probably skin sensitiser and a recognised eye irritant.

Zoxazolamine-[d2] is a labelled version of Zoxazolamine. Zoxazolamine is a muscle relaxant that is no longer marketed.

ZP 1609, a small modified dipeptide, has been identified as a potent and selective second generation gap junction modifier with oral bioavailability. It is a pharmalogical agent with a favorable clinical safety profile and potential antiarrhythmic efficacy, which is confirmed in phase I clinical trials. It is used for the treatment of atrial fibrillation. It […]

ZP 1609 Hydrochloride is the hydrochloride form of ZP 1609, which is a small modified dipeptide and has been identified as a potent and selective second generation gap junction modifier with oral bioavailability. It is a pharmalogical agent with a favorable clinical safety profile and potential antiarrhythmic efficacy, which is confirmed in phase I clinical […]

ZQ 16 is a selective medium-chain free fatty acid receptor GPR84 agonist (EC50 = 139 nM), displaying no activity at GPR40, GPR41, GPR119 or GPR120 at 100 μM. ZQ 16 activates GPR84-mediated calcium mobilization, inhibits cAMP accumulation, and induces ERK1/2 phosphorylation, receptor desensitization and internalization in vitro.

ZSTK474 is a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, which strongly inhibits cancer cell proliferation. Phosphoinositide 3-kinase (PI3K) is a potential target in cancer therapy. Inhibition of PI3K is believed to induce apoptosis. ZSTK474 effectively inhibited the growth of human cancer xenografts in vivo. ZSTK474 treatment suppressed the expression of nuclear cyclin D1 and Ki67 and […]

Zuclomiphene Ring-[d5] Citrate is a labelled form of Clomiphene Citrate which is found to be an antiestrogenic and a more potent inhibitor of LH secretion than the trans isomer.

Zuclopenthixol is an antagonist at D1 and D2 dopamine receptors. It also has high affinity for alpha1-adrenergic and 5-HT2 receptors, but it has weaker histamine H1 receptor blocking activity, and even lower affinity for muscarinic cholinergic and alpha2-adrenergic receptors. lt is the cis-isomer of clopenthixol. It is an antipsychotic drug belonging the thioxanthene class. It […]

The labelled cis(Z)-form of Clopenthixol. Thioxanthene neuroleptic. Antipsychotic.

Zuclopenthixol is a typical antipsychotic drug that belongs to thioxanthene class. Zuclopenthixol is the cis-isomer of clopenthixol. Zuclopenthixol has not been approved for use in the United States. It is a dopamine D1/D2 receptor antagonist used for the treatment of Schizophrenia.

Zuclopenthixol decanoate is a typical antipsychotic drug belonging to the thioxanthene class. lt has high affinity for both dopamine D1 and D2 receptors, for α1-adrenoceptors and 5-HT2 receptors but has no affinity for cholinergic muscarine receptors. It is used in the maintenance treatment of chronic schizophrenic patients. lt is not approved for use in the […]

Zuclopenthixol dihydrochloride is an antagonist at D1 and D2 dopamine receptors. Zuclopenthixol also has high affinity for alpha1-adrenergic and 5-HT2 receptors, but it has weaker histamine H1 receptor blocking activity, and even lower affinity for muscarinic cholinergic and alpha2-adrenergic receptors. lt is the cis-isomer of clopenthixol. It is an antipsychotic drug belonging the thioxanthene class.

Zuclopenthixol-[d4] Succinate Salt is the labelled succinate salt of Zuclopenthixol. Zuclopenthixol is an antagonist at D1 and D2 dopamine receptors. It also has high affinity for alpha1-adrenergic and 5-HT2 receptors, but it has weaker histamine H1 receptor blocking activity, and even lower affinity for muscarinic cholinergic and alpha2-adrenergic receptors. It is the cis-isomer of clopenthixol. […]

Zunsemetinib is a tyrosine kinase inhibitor.

ZXH 3-26 is a potent and selective BRD4 degrader (DC50 ~ 5 nM).

Zygosporin D is produced by the strain of Zygosporium masonii MFC-612 and Zygosporium mycophylum MFC-702. It is cytotoxic to HeLa cells with ED50 of 0.4 μg/mL. It has anti-tumor and anti-inflammatory properties.

Zygosporin E is produced by the strain of Zygosporium masonii MFC-612 and Zygosporium mycophylum MFC-702. It is cytotoxic to HeLa cells with ED50 of 0.4 μg/mL. It has anti-tumor and anti-inflammatory properties.

Zygosporin F is produced by the strain of Zygosporium masonii MFC-612 and Zygosporium mycophylum MFC-702. It is cytotoxic to HeLa cells with ED50 of >10 μg/mL. It has anti-tumor and anti-inflammatory properties.

Zygosporin G is produced by the strain of Zygosporium masonii MFC-612 and Zygosporium mycophylum MFC-702. It is cytotoxic to HeLa cells with ED50 of 0.68 μg/mL. It has anti-tumor and anti-inflammatory properties.